Literature DB >> 3733278

Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers.

H Bun, P Coassolo, F Gouezo, A Serradimigni, J P Cano.   

Abstract

The pharmacokinetic behavior of clobazam and its main metabolite, norclobazam, was investigated in healthy subjects after single dose administration, repeated dose administration (28 days) and discontinuation of the treatment (15-day follow-up). The aim of the study was to confirm the time-invariance of the clobazam and/or norclobazam kinetics, in order to evaluate the predictive value of the single dose parameters for chronic administration of this drug. The comparisons of parameters after single dose and for 15 days following cessation of chronic administration, experimental and simulated plasma level-time courses, experimental and calculated steady-state minimum plasma concentrations, and half-life values at apparent and deep elimination phase, indicate a time-invariant behavior of clobazam, whereas the norclobazam pharmacokinetics appeared to be clearly time-dependent. The clinical importance of this difference cannot be adequately assessed until more is known about the contribution of norclobazam to the overall effect of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733278

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  3 in total

Review 1.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

2.  A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Pharm Res       Date:  2014-07-23       Impact factor: 4.200

Review 3.  A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam.

Authors:  Dwain Tolbert; Frank Larsen
Journal:  J Clin Pharmacol       Date:  2018-10-04       Impact factor: 3.126

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.